CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 227 enrolled
Drug / intervention
Dalcetrapib +1 moredrug
Likely dose
Dalcetrapib 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04676867
NCT04676867Phase 2Completed
CompareCT.gov

A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

DalCor Pharmaceuticals·interventional·Posted Dec 21, 2020·Updated Dec 7, 2022

In Brief

A Phase 2 clinical trial evaluating Dalcetrapib and Placebo for Covid19. Completed, enrolled 227 participants across 1 site.

Detailed Summary

This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesCanada
CollaboratorsThe Montreal Health Innovations Coordinating Center (MHICC), Covance

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 21, 2020
Enrollment StartJan 11, 2021
Primary CompletionMay 17, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.5 years ago

Interventions

Dalcetrapibdrug

Dalcetrapib 300 mg Film-Coated Tablets

Placeboother

Placebo Tablets